Bioreactor-Generated hiPSC Cardiomyocytes for Engineered Heart Tissue Models

This poster highlights the development of a scalable human iPSC-derived engineered heart tissue (EHT) platform, combining Ncardia’s bioreactor-generated ventricular cardiomyocytes with Propria’s MyoPod® and MyoLab® technologies to create physiologically relevant cardiac microphysiological systems. 

Download it now for a closer look at:

• How large-scale bioreactor manufacturing enables reproducible generation of high-purity ventricular cardiomyocytes suitable for engineered tissue applications 
  
• How Ncyte® ventricular cardiomyocytes form structurally organized and spontaneously beating engineered heart tissues within the MyoPod® platform
• Functional contractility data demonstrating mature cardiac characteristics, including β-adrenergic responsiveness and physiological force-frequency relationships
• How the MyoLab® platform enables real-time assessment of contractility, stretch response, and tissue dynamics in engineered cardiac tissues

• Why integrating scalable cell manufacturing with microphysiological systems improves reproducibility and physiological relevance for cardiac research and therapeutic testing